“What is now proved was once only imagined.” –William Blake
Origins in Folk Medicine
Although there is no established record of when plants were first used for medicine purposes, plants as healing agents with clays and soils are ancient. Mixing these elements became ancient medicine practiced in Egypt, China, India, and many other cultures for 1000’s years.
Aboriginal people are still known to directly apply specific types of plants and soils onto their fresh wounds. Mud, or, more accurately, sediment, was carefully selected from particular waterholes to relieve and act as a physical barrier to retard or even kill infection on open wounds.
During the Age of Enlightenment, scientists began to move from botanical to synthetic drugs through organic chemical synthesis. To provide consumers with protection and control over their use, the government created various laws and regulations. These vary in developing countries governing the patenting, testing, safety, efficacy, marketing, and distribution of each drug.
Producing a drug creates a high cost to develop a claim, clinical trials, and a consistent manufacturing process of stability in a controlled cGMP facility. This high cost makes the non patentable ancient medicine unable to become a drug and claim any form of efficacy, disallowing their low cost and benefits simply because there are no financial resources to do so.
The founders of the Ionic Alliance Foundations quest was developed over investigating specific exothermic chemical reactions that would occur using synthetic chemicals easily accessible in today’s markets. These reactions were isolated and simulated in controlled pharmaceutical production methods to acquire nature’s secrets in a tolerance-oriented repeatable formulation.
Over many years of exploring the actions of ancient medicine and the current requirements of the regulations, our inventors developed a new method of delivery to a biological system.
Ion Biotechnology® Aqueous Ligand
The Ion Biotechnology® Aqueous Ligand “IBAL” is a coordination complex of molecules with a polarized hexaaqua ligand system of ionic metals and salts. An IBAL is a synthesized ionophore that actively transports free ions through cell membranes within the cellular environment. A natural carrying system of molecules equilibrated ionic complexes and electrons that target cellular metabolism deliver a biological system’s biologically desired function.
It consists of a central metal atom or cation bonded to one or more ligands in an H2O soup of free ions, ionic salts, and molecules containing one or more pairs of electrons that may be shared with the hexaaqua metal cations. The metal ion in the solution does not exist in isolation but in combination with shifting ligands.
Current IBAL formulations in a ligand structure are Hydrogen, Oxygen, Ammine, Sulfur, Copper, Zinc, Magnesium, Manganese, Selenium. IBAL ratios are formula-specific, designed, and dose-dependent for the purpose and efficacy of each finished product.
The IBAL Science
In Science, Chemistry, and Biology, there are centuries of theories. When “the need for” uses innovation to develop physical substances that address a combination of these theories, it becomes an invention of a composition.
Ion Biotechnology® relates to a combination of sciences in inorganic/organic chemistry, redox values, pH, molecular biology, pharmacokinetics to treat mammalian cells and destroy harmful anaerobic cells to establish biological homeostasis.
There is a global need for improved treatment regimens that are more effective, safe, tolerable, reduced side-effects, shorter in duration, and affordable due to reduced manufacturing costs. A solution having the ease of administration, access, distribution, and extended storage life for low-income and remote localities.
Society needs a nontoxic delivery system that is designed to target biological functions naturally. A method of delivery that can be used safely over a multitude of regulated sectors in personal care, nutrition, and drug delivery.
A preventative, adjunct, or primary therapy based on the individual’s economic or efficacious need. A process to manufacture that is cost-effective, repeatable, stable, and scalable. Antibiotics, one of the greatest inventions in modern medicine, now have a alternative innovative natural complement.
The need for a method of disease prevention allowing for continued research in redox medicine (pro-oxidant and antioxidant agents in cells) and biologic systems therapeutic uses of excitation energies in complex ion structures that deliver positive bonding (“cations”) to oxidative free radicals (“anions”).
Redox biology is the building block of redox switches, and redox relays in clinical proteomics and metabolomics to reduce oxidative and nitrosative stress.
Exogenous nutrient elements modulate the energetic metabolism responses that are prerequisites for cellular homeostasis and metabolic physiology. Specifically, the delivery of micronutrients in the form of metals is critical in oxidative stress and cytoprotection processes. Commonly administered minerals and drugs are not in a highly bioavailable form nor target the immediate therapeutic or nutritional need. They are widely unable to cross through a hydrophobic lipid bilayer membrane or have a natural therapeutic purpose. Many molecules or ions will spread and or diffuse from where they are more concentrated to where they are less concentrated until they are equally distributed in that cellular space, a passive transport.
Small molecule drugs widely disburse and may target all cell types, have multiple side effects, and may not be able to travel to the cell or correctly influence extracellular pathways adequately.
The Ion Biotechnology® Aqua Ligand ” IBAL ” provides a polarized active transport across cell membranes.
The osmotic pressure of water (hexaaqua ligand) creates dispersion of free ions facilitated by polarity and size (small molecular weight) in the interstitial fluids directly through the membrane’s lipid bilayer and into the membrane cytoplasm within the cell, as a natural active transport.
The Ion Biotechnology® Aqueous Ligand (IBAL) has been manufactured and researched in these completed complexes obtaining pH levels, Redox values (ORP), and Metal cation ratios described in the invention. ION-ZC1 for research, ION-ZCM1 as an API candidate in a drug master file, and Ion Gel ZCM-25® as a medical device and drug candidate.
Multiple in-vitro, in-vivo, and preclinical animal and human trials have been performed, supporting the IBAL safety, components, efficacy, and modes of action in biological systems.
Opportunities in life are meant to be utilized and invested in